Cystic Fibrosis — Research Summary
Printed from RareWays (rareways.com.au) on 10 June 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Correspondence: 'CFTR variants in bronchiectasis'.
Yang Yuanli — Pulmonology (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41696981/
- 2.
Comment on "Prevalence, type, and clinical implications of CFTR variants in bronchiectasis".
Priya Shanvi et al. — Pulmonology (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41684272/
- 3.
'The Hero's journey': Narratives on the transition to motherhood with cystic fibrosis.
Haines Alena J et al. — British journal of health psychology (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41804034/
- 4.
Gegen Qinlian decoction alleviates bacterial diarrhea via Lactobacillus amylovorus-modulated restoration of colonic water transport through the cAMP/CFTR/AQP3 pathway.
Luo Zhen-Ye et al. — Microbial pathogenesis (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41802655/
- 5.
L-ascorbic acid exerts anti-microbial and anti-virulence effects against multi-drug resistant Burkholderia cepacia complex.
Bhujbal Sourabh Rajendra et al. — Microbial pathogenesis (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41763415/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
Recruiting — Phase 2 — CSL Behring
https://clinicaltrials.gov/study/NCT07048262
- 2.
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
Recruiting — Phase 3 — Vertex Pharmaceuticals Incorporated
https://clinicaltrials.gov/study/NCT05422222
- 3.
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
Recruiting — Phase 1 — Respirion Pharmaceuticals Pty Ltd
https://clinicaltrials.gov/study/NCT06016088
- 4.
Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People with Cystic Fibrosis
Recruiting — Phase 1 — Cystetic Medicines, Inc.
https://clinicaltrials.gov/study/NCT05802264
- 5.
Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta
Recruiting — Phase 2 — Sionna Therapeutics Inc.
https://clinicaltrials.gov/study/NCT07108153
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Cystic Fibrosis
Cystic fibrosis is a genetic condition that causes thick, sticky mucus to build up in the lungs and digestive system. It affects breathing and digestion. Treatments have advanced significantly, and many people with CF now live into adulthood and beyond.
Most Recent Research
Common Questions
What is Cystic Fibrosis?
Cystic fibrosis is a genetic condition that causes thick, sticky mucus to build up in the lungs and digestive system. It affects breathing and digestion. Treatments have advanced significantly, and many people with CF now live into adulthood and beyond.
How many clinical trials are available for Cystic Fibrosis?
RareWays currently indexes 1317 clinical trials for Cystic Fibrosis, of which 149 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Cystic Fibrosis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Cystic Fibrosis.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.